<DOC>
	<DOCNO>NCT00002018</DOCNO>
	<brief_summary>To conduct double-blind , randomize , dose range study orally administer low dose interferon alfa-n3 ( IFN-An3 ) immunomodulator treatment symptomatic HIV+ subject .</brief_summary>
	<brief_title>Double-Blind , Randomized , Dose Ranging Study Alferon LDO ( Low Dose Oral Interferon Alfa-n3 ( Human Leukocyte Derived ) ) HIV+ Subjects</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Zidovudine ( AZT ) . Didanosine ( ddI ) Patients must : Seropositivity HIV1 ELISA Western blot . At least 1 HIVrelated clinical symptom opportunistic infection list protocol . Written informed consent . If already zidovudine ( AZT ) didanosine ( ddI ) , must therapy least 75 90 day prior study entry . Prior Medication : Allowed : Zidovudine ( AZT ) . Didanosine ( ddI ) Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Major active opportunistic infection require active care within 2 week study entry . Evidence chronic hepatitis severe liver dysfunction : albumin &lt; 2 g/dl SGOT SGPT &gt; 5 x upper limit normal prothrombin time &gt; 1.5 x upper limit normal ) . Other active gastrointestinal , renal , respiratory , endocrine , hematologic , cardiovascular , neurologic , psychiatric disorder . Transfusion dependency define require &gt; 1 unit pack red blood cell ( RBC ) per month within 3 month prior study entry . Concurrent Medication : Excluded : Experimental medication didanosine ( ddI ) . Chronic prophylactic use topical systemic fungal medication ketoconazole , fluconazole , clotrimazole . Chronic prophylactic use topical systemic antiviral medication acyclovir ganciclovir except zidovudine ( AZT ) didanosine ( ddI ) . Patients follow exclude : Asymptomatic study entry . Presence antibodies interferon due prior therapy . Hospitalization within 2 week study entry . Transfusion dependency . Unwilling unable give inform consent . Evidence concurrent organ dysfunction list Exclusion CoExisting Conditions . Unlikely unable comply requirement protocol . Prior Medication : Excluded within 6 week study entry : Interferons . Excluded within 45 day study entry : Immunosuppressive agent . Chemotherapy . Steroids . Immunomodulators . Isoprinosine . BCG vaccine . Prior Treatment : Excluded within 2 week study entry : Hospitalization . Active intravenous ( IV ) drug abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 1993</verification_date>
	<keyword>Interferon Type I</keyword>
</DOC>